An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies

References

• Du L, Tai W, Zhou Y, et al. Vaccines for the prevention against the threat of MERS-CoV. Expert Rev Vaccines. 2016;15(9):1123–1134.
   PubMed Web of Science ®Google Scholar
• Chan J, Lau S, Woo P. The emerging novel Middle East respiratory syndrome coronavirus: the “knowns” and “unknowns”. J Formos Med Assoc. 2013;112(7):372–381.
   PubMed Web of Science ®Google Scholar
• Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5(4):562–569.
   PubMed Web of Science ®Google Scholar
• Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV–a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226–236.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Coronavirus disease 2019 (COVID-19) Weekly Epidemiological Update. [cited August 24, 2020]. Available from https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200824-weekly-epi-update.pdf?sfvrsn=806986d1_4.
   Google Scholar
• Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–1820.
   PubMed Web of Science ®Google Scholar
• WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). [cited 2019] Available from: https://www.who.int/emergencies/mers-cov/en/.
   Google Scholar
• Park JE, Jung S, Kim A, et al. MERS transmission and risk factors: a systematic review. BMC Public Health. 2018;18(1):574.
   PubMedGoogle Scholar
• Korea Centers for Disease Control and Prevention. Middle East respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015. Osong Public Health Res Perspect. 2015;6(4):269–278.
   PubMedGoogle Scholar
• Li F, Du L. MERS coronavirus: an emerging zoonotic virus. Viruses. 2019;11(7):E663.
   PubMed Web of Science ®Google Scholar
• Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–254.
   PubMed Web of Science ®Google Scholar
• Shang J, Ye G, Shi K, et al. Structure basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221–224.
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454.
   PubMed Web of Science ®Google Scholar
• Wang Q, Qi J, Yuan Y, et al. Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host Microbe. 2014;16(3):328–337.
   PubMed Web of Science ®Google Scholar
• Yang Y, Du L, Liu C, et al. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc Natl Acad Sci U S A. 2014;111(34):12516–12521.
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu C, Du L, et al. Two mutations were critical for bat-to-human transmission of Middle East respiratory syndrome coronavirus. J Virol. 2015;89(17):9119–9123.
   PubMed Web of Science ®Google Scholar
• Woo PCY, Lau SKP, Chen Y, et al. Rapid detection of MERS coronavirus-like viruses in bats: pote1ntial for tracking MERS coronavirus transmission and animal origin. Emerg Microbes Infect. 2018;7(1):18.
   PubMedGoogle Scholar
• Olival KJ, Hosseini PR, Zambrana-Torrelio, et al. Host and viral traits predict zoonotic spillover from mammals. Nature. 2017;546(7660):646–650.
   PubMed Web of Science ®Google Scholar
• Haagmans BL, Al Dhahiry SH, Reusken CB, et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis. 2014;14(2):140–145.
   PubMed Web of Science ®Google Scholar
• Azhar EI, El-Kafrawy SA, Farraj SA, et al. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med. 2014;370(26):2499–2505.
   PubMed Web of Science ®Google Scholar
• Kayali G, Peiris M. A more detailed picture of the epidemiology of Middle East respiratory syndrome coronavirus. Lancet Infect Dis. 2015;15(5):495–497.
   PubMed Web of Science ®Google Scholar
• Muller MA, Corman VM, Jores J, et al. MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983-1997. Emerg Infect Dis. 2014;20(12):2093–2095.
   PubMed Web of Science ®Google Scholar
• Muller MA, Meyer B, Corman VM, et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect Dis. 2015;15(5):559–564.
   PubMed Web of Science ®Google Scholar
• Adney DR, van Doremalen N, Brown VR, et al. Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg Infect Dis. 2014;20(12):1999–2005.
   PubMed Web of Science ®Google Scholar
• Khalafalla AI, Lu X, Al-Mubarak AI, et al. MERS-CoV in upper respiratory tract and lungs of dromedary camels, Saudi Arabia, 2013-2014. Emerg Infect Dis. 2015;21(7):1153–1158.
   PubMed Web of Science ®Google Scholar
• Killerby ME, Biggs HM, Midgley CM, et al. Middle East respiratory syndrome coronavirus transmission. Emerg Infect Dis. 2020;26(2):191–198.
   PubMed Web of Science ®Google Scholar
• Memish ZA, Cotten M, Meyer B, et al. Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. Emerg Infect Dis. 2014;20(6):1012–1015.
   PubMed Web of Science ®Google Scholar
• Sikkema RS, Farag E, Himatt S, et al. Risk factors for primary Middle East respiratory syndrome coronavirus infection in camel workers in Qatar during 2013-2014: a case-control study. J Infect Dis. 2017;215(11):1702–1705.
   PubMed Web of Science ®Google Scholar
• Alshukairi AN, Zheng J, Zhao J, et al. High prevalence of MERS-CoV infection in camel workers in Saudi Arabia. mBio. 2018;9(5):e01985–18.
   PubMed Web of Science ®Google Scholar
• Drosten C, Meyer B, Muller MA, et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med. 2014;371(9):828–835.
   PubMed Web of Science ®Google Scholar
• Kim KH, Tandi TE, Choi JW, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications. J Hosp Infect. 2017;95(2):207–213.
   PubMed Web of Science ®Google Scholar
• van Boheemen S, de Graaf M, Lauber C, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio. 2012;3(6):e00473–12.
   PubMed Web of Science ®Google Scholar
• Du L, Yang Y, Zhou Y, et al. MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets. 2017;21(2):131–143.
   PubMed Web of Science ®Google Scholar
• Zhang N, Jiang S, Du L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines. 2014;13(6):761–764.
   PubMed Web of Science ®Google Scholar
• Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013;500(7461):227–231.
   PubMed Web of Science ®Google Scholar
• Chen Y, Rajashankar KR, Yang Y, et al. Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J Virol. 2013;87(19):10777–10783.
   PubMed Web of Science ®Google Scholar
• Li W, Hulswit RJG, Widjaja I, et al. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. Proc Natl Acad Sci U S A. 2017;114(40):E8508–E8517.
   Google Scholar
• Widagdo W, Okba NMA, Li W, et al. Species-specific colocalization of Middle East respiratory syndrome coronavirus attachment and entry receptors.. J Virol. 2019;93(16):e00107–19.
   PubMedGoogle Scholar
• Park YJ, Walls AC, Wang Z, et al. Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors. Nat Struct Mol Biol. 2019;26(12):1151–1157.
   Google Scholar
• Lu L, Liu Q, Zhu Y, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014;5:3067.
   PubMed Web of Science ®Google Scholar
• Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol. 2003;82(2):53–73.
   PubMed Web of Science ®Google Scholar
• Wang N, Shi X, Jiang L, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 2013;23(8):986–993.
   PubMed Web of Science ®Google Scholar
• Bosch BJ, Raj VS, Haagmans BL. Spiking the MERS-coronavirus receptor. Cell Res. 2013;23(9):1069–1070.
   PubMed Web of Science ®Google Scholar
• Shirato K, Kawase M, Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol. 2013;87(23):12552–12561.
   PubMed Web of Science ®Google Scholar
• Kleine-Weber H, Elzayat MT, Hoffmann M, et al. Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein. Sci Rep. 2018;8(1):16597.
   PubMedGoogle Scholar
• Qian Z, Dominguez SR, Holmes KV. Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation. PloS One. 2013;8(10):e76469.
   PubMed Web of Science ®Google Scholar
• Earnest JT, Hantak MP, Li K, et al. The tetraspanin CD9 facilitates MERS-coronavirus entry by scaffolding host cell receptors and proteases. PLoS Pathog. 2017;13(7):e1006546.
   PubMed Web of Science ®Google Scholar
• Pallesen J, Wang N, Corbett KS, et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017;114(35):E7348–E7357.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Cao D, Zhang Y, et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat Commun. 2017;8:15092.
   PubMed Web of Science ®Google Scholar
• Wang N, Rosen O, Wang L, et al. Structural definition of a neutralization-sensitive epitope on the MERS-CoV S1-NTD. Cell Rep. 2019;28(13):3395–3405.
   PubMed Web of Science ®Google Scholar
• Goddard TD, Huang CC, Frrrin TE. Visualizing density maps with UCSF Chimera. J Struct Biol. 2007;157(1):281–287.
   PubMed Web of Science ®Google Scholar
• Yan-Hua Li, Chen-Yu Hu, Nan-Ping Wu, et al. Molecular characteristics, functions, and related pathogenicity of MERS-CoV proteins. Engineering. 2019;5(5):940–947.
   Web of Science ®Google Scholar
• Surya W, Li Y, Verdia-Baguena C, et al. MERS coronavirus envelope protein has a single transmembrane domain that forms pentameric ion channels. Virus Res. 2015;201:61–66.
   PubMed Web of Science ®Google Scholar
• Almazan F, DeDiego ML, Sola I, et al. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. mBio. 2013;4(5):e00650–13.
   PubMed Web of Science ®Google Scholar
• Papageorgiou N, Lichiere J, Baklouti A, et al. Structural characterization of the N-terminal part of the MERS-CoV nucleocapsid by X-ray diffraction and small-angle X-ray scattering. Acta Crystallogr D Struct Biol. 2016;72(Pt 2):192–202.
   PubMedGoogle Scholar
• Wang YS, Chang CK, Hou MH. Crystallographic analysis of the N-terminal domain of Middle East respiratory syndrome coronavirus nucleocapsid protein. Acta Crystallogr F Struct Biol Commun. 2015;71(Pt 8):977–980.
   PubMedGoogle Scholar
• Cho CC, Lin MH, Chuang CY, et al. Macro domain from Middle East respiratory syndrome coronavirus (MERS-CoV) is an efficient ADP-ribose binding module: Crystal structure and biochemical studies. J Biol Chem. 2016;291(10):4894–4902.
   PubMed Web of Science ®Google Scholar
• Hao W, Wojdyla JA, Zhao R, et al. Crystal structure of Middle East respiratory syndrome coronavirus helicase. PLoS Pathog. 2017;13(6):e1006474.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li L, Yan L, et al. Structural and biochemical characterization of endoribonuclease Nsp15 encoded by Middle East respiratory syndrome coronavirus. J Virol. 2018;92(22):e00893–18.
   PubMed Web of Science ®Google Scholar
• Menachery VD, Gralinski LE, Mitchell HD, et al. Middle East respiratory syndrome coronavirus nonstructural protein 16 is necessary for interferon resistance and viral pathogenesis. mSphere. 2017;2(6):e00346–17.
   PubMed Web of Science ®Google Scholar
• Lee JY, Bae S, Myoung J. Middle East respiratory syndrome coronavirus-encoded ORF8b strongly antagonizes IFN-beta promoter activation: its implication for vaccine design. J Microbiol. 2019;57(9):803–811.
   PubMed Web of Science ®Google Scholar
• Scobey T, Yount BL, Sims AC, et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci U S A. 2013;110(40):16157–16162.
   PubMed Web of Science ®Google Scholar
• Wang C, Zheng X, Gai W, et al. Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice. Antiviral Res. 2017;140:55–61.
   PubMed Web of Science ®Google Scholar
• Li E, Chi H, Huang P, et al. A novel bacterium-like particle vaccine displaying the MERS-CoV receptor-binding domain induces specific mucosal and systemic immune responses in mice. Viruses. 2019;11(9):E799.
   PubMed Web of Science ®Google Scholar
• Muthumani K, Falzarano D, Reuschel EL, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med. 2015;7(301):301ra132.
   PubMed Web of Science ®Google Scholar
• Haagmans BL, van den Brand JM, Raj VS, et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science. 2016;351(6268):77–81.
   PubMed Web of Science ®Google Scholar
• Du L, Tai W, Yang Y, et al. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat Commun. 2016;7:13473.
   PubMed Web of Science ®Google Scholar
• Coleman CM, Venkataraman T, Liu YV, et al. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine. 2017;35(12):1586–1589.
   PubMed Web of Science ®Google Scholar
• Chi H, Zheng X, Wang X, et al. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. Vaccine. 2017;35(16):2069–2075.
   PubMed Web of Science ®Google Scholar
• Al-Amri SS, Abbas AT, Siddiq LA, et al. Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein. Sci Rep. 2017;7:44875.
   PubMed Web of Science ®Google Scholar
• Wang L, Shi W, Joyce MG, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015;6:7712.
   PubMed Web of Science ®Google Scholar
• Volz A, Kupke A, Song F, et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. J Virol. 2015;89(16):8651–8656.
   PubMed Web of Science ®Google Scholar
• Guo X, Deng Y, Chen H, et al. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology. 2015;145(4):476–484.
   PubMed Web of Science ®Google Scholar
• Song F, Fux R, Provacia LB, et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol. 2013;87(21):11950–11954.
   PubMed Web of Science ®Google Scholar
• Ababneh M, Alrwashdeh M, Khalifeh M. Recombinant adenoviral vaccine encoding the spike 1 subunit of the Middle East respiratory syndrome coronavirus elicits strong humoral and cellular immune responses in mice. Vet World. 2019;12(10):1554–1562.
   PubMed Web of Science ®Google Scholar
• Liu R, Wang J, Shao Y, et al. A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization. Antiviral Res. 2018;150:30–38.
   PubMed Web of Science ®Google Scholar
• Bodmer BS, Fiedler AH, Hanauer JRH, et al. Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model. Virology. 2018;521:99–107.
   PubMed Web of Science ®Google Scholar
• Langenmayer MC, Lulf-Averhoff AT, Adam-Neumair S, et al. Distribution and absence of generalized lesions in mice following single dose intramuscular inoculation of the vaccine candidate MVA-MERS-S. Biologicals. 2018;54:58–62.
   PubMed Web of Science ®Google Scholar
• Kim E, Okada K, Kenniston T, et al. Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB/c mice. Vaccine. 2014;32(45):5975–5982.
   PubMed Web of Science ®Google Scholar
• Hashem AM, Algaissi A, Agrawal AS, et al. A highly immunogenic, protective, and safe adenovirus-based vaccine expressing Middle East respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model. J Infect Dis. 2019;220(10):1558–1567.
   PubMed Web of Science ®Google Scholar
• Kim MH, Kim HJ, Chang J. Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length spike protein of Middle East respiratory syndrome coronavirus. PLoS One. 2019;14(7):e0220196.
   PubMed Web of Science ®Google Scholar
• Alharbi NK, Qasim I, Almasoud A, et al. Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels. Sci Rep. 2019;9(1):16292.
   PubMedGoogle Scholar
• Jia W, Channappanavar R, Zhang C, et al. Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection. Emerg Microbes Infect. 2019;8(1):760–772.
   PubMed Web of Science ®Google Scholar
• Alharbi NK, Padron-Regalado E, Thompson CP, et al. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralizing antibodies and cellular immune responses in mice. Vaccine. 2017;35(30):3780–3788.
   PubMed Web of Science ®Google Scholar
• Ozharovskaia TA, Zubkova OV, Dolzhikova IV, et al. Immunogenicity of different forms of Middle East respiratory syndrome S glycoprotein. Acta Naturae. 2019;11(1):38–47.
   PubMed Web of Science ®Google Scholar
• Malczyk AH, Kupke A, Prufer S, et al. A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J Virol. 2015;89(22):11654–11667.
   PubMed Web of Science ®Google Scholar
• Du L, Zhao G, Kou Z, et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol. 2013;87(17):9939–9942.
   PubMed Web of Science ®Google Scholar
• Ma C, Li Y, Wang L, et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine. 2014;32(18):2100–2108.
   PubMed Web of Science ®Google Scholar
• Ma C, Wang L, Tao X, et al. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments–the importance of immunofocusing in subunit vaccine design. Vaccine. 2014;32(46):6170–6176.
   PubMed Web of Science ®Google Scholar
• Lan J, Yao Y, Deng Y, et al. Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine. 2015;2(10):1438–1446.
   PubMed Web of Science ®Google Scholar
• Adney DR, Wang L, van Doremalen N, et al. Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas. Viruses. 2019;11(3):E212.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yang Y, Huang J, et al. Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain. Viruses. 2019;11(1):E60.
   PubMed Web of Science ®Google Scholar
• Mou H, Raj VS, van Kuppeveld FJ, et al. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol. 2013;87(16):9379–9383.
   PubMed Web of Science ®Google Scholar
• Lan J, Deng Y, Chen H, et al. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS One. 2014;9(11):e112602.
   PubMed Web of Science ®Google Scholar
• Tai W, Wang Y, Fett CA, et al. Recombinant receptor-binding domains of multiple Middle East respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants. J Virol. 2016;91(1):e01651–16.
   PubMed Web of Science ®Google Scholar
• Tai W, Zhao G, Sun S, et al. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology. 2016;499:375–382.
   PubMed Web of Science ®Google Scholar
• Nyon MP, Du L, Tseng CK, et al. Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine. 2018;36(14):1853–1862.
   PubMed Web of Science ®Google Scholar
• Du L, Kou Z, Ma C, et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PloS One. 2013;8(12):e81587.
   PubMed Web of Science ®Google Scholar
• Zhang N, Channappanavar R, Ma C, et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol. 2016;13(2):180–190.
   PubMed Web of Science ®Google Scholar
• Tang J, Zhang N, Tao X, et al. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother. 2015;11(5):1244–1250.
   PubMed Web of Science ®Google Scholar
• Wang Y, Tai W, Yang J, et al. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Hum Vaccin Immunother. 2017;13(7):1615–1624.
   PubMed Web of Science ®Google Scholar
• Tao X, Garron T, Agrawal AS, et al. Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol. 2015;90(1):57–67.
   PubMed Web of Science ®Google Scholar
• Jiaming L, Yanfeng Y, Yao D, et al. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine. 2017;35(1):10–18.
   PubMed Web of Science ®Google Scholar
• Lan J, Deng Y, Song J, et al. Significant spike-specific IgG and neutralizing antibodies in mice induced by a novel chimeric virus-like particle vaccine candidate for Middle East respiratory syndrome coronavirus. Virol Sin. 2018;33(5):453–455.
   PubMed Web of Science ®Google Scholar
• Wang C, Zheng X, Gai W, et al. MERS-CoV virus-like particles produced in insect cells induce specific humoral and cellular immunity in rhesus macaques. Oncotarget. 2017;8(8):12686–12694.
   PubMedGoogle Scholar
• Coleman CM, Liu YV, Mu H, et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine. 2014;32(26):3169–3174.
   PubMed Web of Science ®Google Scholar
• Kato T, Takami Y, Kumar Deo V, et al. Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells. J Biotechnol. 2019;306:177–184.
   PubMed Web of Science ®Google Scholar
• Jung SY, Kang KW, Lee EY, et al. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. Vaccine. 2018;36(24):3468–3476.
   PubMed Web of Science ®Google Scholar
• Veit S, Jany S, Fux R, et al. CD8+ T cells responding to the Middle East respiratory syndrome coronavirus nucleocapsid protein delivered by Vaccinia virus MVA in mice. Viruses. 2018;10(12):E718.
   PubMed Web of Science ®Google Scholar
• Deng Y, Lan J, Bao L, et al. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg Microbes Infect. 2018;7(1):60.
   PubMed Web of Science ®Google Scholar
• Agrawal AS, Tao X, Algaissi A, et al. Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother. 2016;12(9):2351–2356.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Jiang S, Du L. Prospects for a MERS-CoV spike vaccine. Expert Rev Vaccines. 2018;17(8):677–686.
   PubMed Web of Science ®Google Scholar
• Modjarrad K, Roberts CC, Mills KT, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019;19(9):1013–1022.
   PubMed Web of Science ®Google Scholar
• A clinical trial to determine the safety and immunogenicity of healthy candidate MERS-CoV vaccine (MERS002). [cited Dec 26, 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT04170829.
   Google Scholar
• Safety, tolerability and immunogenicity of vaccine candidate MVA-MERS-S. [cited Dec 26, 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT03615911.
   Google Scholar
• Chen WH, Tao X, Agrawal A, et al. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with alum induces protective immunity and reduces immune enhancement. bioRxiv. 2020;098079. DOI:10.1101/2020.05.15.098079.
   Google Scholar
• Chen WH, Du L, Chag SM, et al. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccin Immunother. 2014;10(3):648–658.
   PubMed Web of Science ®Google Scholar
• Wang SF, Tseng SP, Yen CH, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun. 2014;451(2):208–214.
   PubMed Web of Science ®Google Scholar
• Yip MS, Leung HL, Li PH, et al. Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS. Hong Kong Med J. 2016;22(3 Suppl 4):25–31.
   PubMedGoogle Scholar
• Czub M, Weingartl H, Czub S, et al. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine. 2005;23(17–18):2273–2279.
   PubMed Web of Science ®Google Scholar
• Agrawal AS, Garron T, Tao X, et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol. 2015;89(7):3659–3670.
   PubMed Web of Science ®Google Scholar
• Zhao G, Jiang Y, Qiu H, et al. Multi-organ damage in human dipeptidyl peptidase 4 transgenic mice infected with Middle East respiratory syndrome-coronavirus. PloS One. 2015;10(12):e0145561.
   PubMed Web of Science ®Google Scholar
• Li K, Wohlford-Lanane CL, Channappanavar R, et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc Natl Acad Sci U S A. 2017;114(15):E3119–E3128.
   PubMed Web of Science ®Google Scholar
• Li K, Wohlford-Lanane C, Perlman S, et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J Infect Dis. 2016;13(5):712–722.
   Google Scholar
• Zhao J, Li K, Wohlford-Lanane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A. 2014;111(13):4970–4975.
   PubMed Web of Science ®Google Scholar
• Adney DR, Wang L, Doremalen NV, et al. Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas. Viruses. 2019;11(3):212.
   PubMed Web of Science ®Google Scholar
• Luo CM, Wang N, Yang XL, et al. Discovery of novel bat coronaviruses in south China that use the same receptor as Middle East respiratory syndrome coronavirus. J Virol. 2018;92(13):e00116–18.
   PubMed Web of Science ®Google Scholar
• Lau SKP, Zhang L, Luk HKH, et al. Receptor usage of a novel bat lineage C betacoronavirus reveals evolution of Middle East respiratory syndrome-related coronavirus spike proteins for human dipeptidyl peptidase 4 binding. J Infect Dis. 2018;218(2):197–207.
   PubMed Web of Science ®Google Scholar
• Wan Y, Shang J, Graham R, et al. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virol. 2020;94(7):pii:e00127-20.
   Web of Science ®Google Scholar
• Shi J, Wen Z, Zhong G, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science. 2020;pii:eabb7015.
   Google Scholar
• Yu P, Qi F, Xu Y. et al. Age-related rhesus macaque models of COVID-19. Animal Model Exp Med. 2020;3(1):93–97.
   PubMedGoogle Scholar
• Kim YI, Kim SG, Kim SM, et al. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe. 2020;27(5):704–709.
   PubMed Web of Science ®Google Scholar
• Bao LL, Deng W, Huang BY, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. 2020. DOI:10.1038/s41586-020-2312-y
   Google Scholar
• Dinnon KH, Leist SR, Schafer A, et al. A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures. [cited May 7, 2020]. Available from: bioRxiv preprint. https://doi.org/10.1101/2020.05.06.081497.
   Google Scholar
• Campbell M, Writer S 13 COVID-19 vaccines are in human clinical trials-what are they? [ cited June 29, 2020]. Available from: https://www.technologynetworks.com/biopharma/blog/13-covid-19-vaccines-are-in-human-clinical-trials-what-are-they-336738
   Google Scholar
• Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305–306.
   Google Scholar